Now Reading
Biogen C.E.O. to Step Down Following Launch of Alzheimer’s Drug, Aduhelm

Biogen C.E.O. to Step Down Following Launch of Alzheimer’s Drug, Aduhelm

Biogen C.E.O. to Step Down Following Launch of Alzheimer’s Drug, Aduhelm

Biogen stated on Tuesday that it might substitute its chief govt and successfully hand over on advertising a high-profile Alzheimer’s drug that has been a industrial failure since its controversial approval almost a yr in the past.

Michel Vounatsos, who has led the drug maker for over 5 years and presided over the approval and launch of the drug, often called Aduhelm, will stay in his position till a successor is appointed, Biogen stated.

Biogen stated it deliberate to “considerably remove” its spending on the drug after Medicare formally determined final month to sharply restrict its protection of Aduhelm.

The Meals and Drug Administration authorized Aduhelm in June. It was the primary new remedy for Alzheimer’s in almost twenty years. It had been extensively anticipated to turn out to be a blockbuster drug inside a number of years, producing billions of {dollars} yearly for Biogen. However the approval was overshadowed by concern in regards to the drug’s unproven advantages and critical security dangers, in addition to in regards to the course of by which the F.D.A. had greenlighted it.

See Also

Medical doctors, insurers, and sufferers and their households haven’t embraced Aduhelm. On Tuesday, Biogen reported that the drug had introduced in simply $2.8 million in income within the first three months of this yr, after producing solely $3 million in 2021. Biogen initially priced the drug at $56,000 per yr for the typical affected person earlier than halving the price in response to weak early gross sales.

Aduhelm had been anticipated to pressure authorities well being budgets. However Medicare determined to pay for the drug just for individuals who obtain it as individuals in a medical trial. Final month, Biogen stated it might withdraw its utility to market the drug within the European Union after drug reviewers indicated that it was unlikely to win approval.

What's Your Reaction?
Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0
View Comments (0)

Leave a Reply

Your email address will not be published.

© 2021 Brand Rator. All Rights Reserved.

Scroll To Top